Cargando…

CD49f and CD61 identify Her2/neu-induced mammary tumor initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling

HER2/Neu is overexpressed in 20-30% of breast cancers and associated with aggressive phenotypes and poor prognosis. For deciphering the role of HER2/Neu in breast cancer, mouse mammary tumor virus (MMTV)-Her2/neu transgenic mice that develop mammary tumors resembling human HER2-subtype breast cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lo, Pang-Kuo, Kanojia, Deepak, Liu, Xinfeng, Singh, Udai P., Berger, Franklin G., Wang, Qian, Chen, Hexin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260386/ https://www.ncbi.nlm.nih.gov/pubmed/21996747 http://dx.doi.org/10.1038/onc.2011.439

Ejemplares similares

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Cytokines and TLR agonists influence the expression of retention integrins CD49a, CD49b and CD103 by T cells
por: Melssen, Marit M, et al.
Publicado: (2015)

Dmp1α Inhibits HER2/neu-Induced Mammary Tumorigenesis
por: Fry, Elizabeth A., et al.
Publicado: (2013)

Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy
por: Rodrigues, Loreta M, et al.
Publicado: (2012)

Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span
por: Provinciali, Mauro, et al.
Publicado: (2017)

Regulation and Functions of α6-Integrin (CD49f) in Cancer Biology
por: Khademi, Rahele, et al.
Publicado: (2023)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
por: Croci, Stefania, et al.
Publicado: (2015)

The induction of apoptosis in human mammary luminal epithelial cells by expression of activated c-neu and its abrogation by glucocorticoids.
por: Harris, R. A., et al.
Publicado: (1995)

Developmental and Lactational Exposure to Dieldrin Alters Mammary Tumorigenesis in Her2/neu Transgenic Mice
por: Cameron, Heather L., et al.
Publicado: (2009)

T(RM) integrins CD103 and CD49a differentially support adherence and motility after resolution of influenza virus infection
por: Reilly, Emma C., et al.
Publicado: (2020)

NEU1 and NEU3 enzymes alter CD22 organization on B cells
por: Ton Tran, Hanh-Thuc, et al.
Publicado: (2022)

Suppression of Her2/Neu mammary tumor development in mda-7/IL-24 transgenic mice
por: Li, You-Jun, et al.
Publicado: (2015)

Accelerated Mammary Tumor Onset in a HER2/Neu Mouse Model Exposed to DDT Metabolites Locally Delivered to the Mammary Gland
por: Johnson, Nakpangi A, et al.
Publicado: (2012)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Frequencies of an Immunogenic HER-2/neu Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer
por: Goulielmaki, Maria, et al.
Publicado: (2023)

Expression and clinical significance of HER2/neu, aromatase P450 and adhesion molecule CD24 in endometrial cancer
por: Guan, Liyun, et al.
Publicado: (2023)

Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice
por: Boggio, Katia, et al.
Publicado: (1998)

CCL2/CCR2 Regulates the Tumor Microenvironment in HER-2/neu-Driven Mammary Carcinomas in Mice
por: Chen, Xuguang, et al.
Publicado: (2016)

Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis
por: Patel, Y, et al.
Publicado: (2018)

Stat3 Is Required to Maintain the Full Differentiation Potential of Mammary Stem Cells and the Proliferative Potential of Mammary Luminal Progenitors
por: Staniszewska, Anna D., et al.
Publicado: (2012)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
por: Puri, Vandana, et al.
Publicado: (2011)

Cytotoxic Activity and Memory T Cell Subset Distribution of in vitro-Stimulated CD8(+) T Cells Specific for HER2/neu Epitopes
por: Kuznetsova, Maria, et al.
Publicado: (2019)

Nonlinear Growth Kinetics of Breast Cancer Stem Cells: Implications for Cancer Stem Cell Targeted Therapy
por: Liu, Xinfeng, et al.
Publicado: (2013)

Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice
por: Bandini, Silvio, et al.
Publicado: (2013)

CD4(+) and CD8(+) T Cells Can Act Separately in Tumour Rejection after Immunization with Murine Pneumotropic Virus Chimeric Her2/neu Virus-Like Particles
por: Andreasson, Kalle, et al.
Publicado: (2010)

CORRIGENDUM: Nonlinear Growth Kinetics of Breast Cancer Stem Cells: Implications for Cancer Stem Cell Targeted Therapy
por: Liu, Xinfeng, et al.
Publicado: (2013)

CD61 promotes the differentiation of canine ADMSCs into PGC-like cells through modulation of TGF-β signaling
por: Fang, Jia, et al.
Publicado: (2017)

CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells
por: Sleeman, Katherine E, et al.
Publicado: (2006)

Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice
por: Nanni, Patrizia, et al.
Publicado: (2001)

Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model
por: Eralp, Yesim, et al.
Publicado: (2004)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

TGF-β1 maintains suppressor function and Foxp3 expression in CD4(+)CD25(+) regulatory T cells
por: Marie, Julien C., et al.
Publicado: (2005)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_c4e0sbgjvc5c39edl8sttqa1qj